ObsEva SA (OBSV)
(Delayed Data from NSDQ)
$13.89 USD
-0.12 (-0.86%)
Updated May 3, 2019 04:13 PM ET
After-Market: $13.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[OBSV]
Reports for Purchase
Showing records 1 - 20 ( 170 total )
Industry: Medical - Biomedical and Genetics
NASDAQ De-Listing Planned; Dropping Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Restructuring Initiatives Reduce Operating Expenses; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Linzagolix Approvability Issues; Restructuring; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Linzagolix Wins European Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Linzagolix Edges Closer to Approval; 1Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Linzagolix Positive European Opinion Received; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Additional EDELWEISS Data Released; 2021 Financials; Lowering PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Linzagolix European Approval Timeline Extension; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Linzagolix EDELWEISS 3 Pivotal Trial Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Linzagolix Positive European Opinion Received; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
More Linzagolix Clinical Data Presented; New Finance Chief; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Linzagolix Application Accepted; 3Q21 Financials; Lowering PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - Dropping Coverage
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Linzagolix NDA Submitted; Multiple Catalysts Ahead in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Linzagolix New Drug Application for Uterine Fibroids Submitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Key Linzagolix Milestones Imminent; 2Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R